FDA has not assured peptide identity or purity regarding a matter involving Mount Sinai.
1 report, 1 independent
Updated Sep 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA has not assured peptide identity or purity regarding a matter involving Mount Sinai.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Mount Sinai
hamlet located within the Town of Brookhaven in Suffolk County, New York, United States
Related events
- Vanta is planning entry into the U.S. peptide market, noting that its advancing platform requires FDA-registered compounding.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- Amy Brenner hopes that a favorable FDA ruling will allow for more peptide products, noting her offices are in Kenwood and Mason.
- Industry bodies are pushing for an expansion of ingredient definitions, involving the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.